Through a collaboration with Pfizer and UK Biobank, AMRA was able to grow its database from 10,000 to 25,000 participants and move the company closer to its goal of analyzing the body composition of 100,000 individuals.

The new data provide norms for several metabolic conditions, such as nonalcoholic fatty liver disease, obesity, and diabetes, that may serve as references in future clinical trials and clinical practice. AMRA researchers also collected and validated new measurements for liver fat values and muscle fat infiltration, which will enable more detailed investigations in metabolic research, the firm said.

Pfizer, BioNTech confirm high efficacy of COVID-19 vaccine up to 6 months
Pfizer-BioNTech's BNT162b2 COVID-19 vaccine is 91.3% effective against the virus six days through up to six months after the second dose, according to...

Pfizer-BioNTech's COVID-19 vaccine shows 100% effectiveness in adolescents
Pfizer-BioNTech's BNT162b2 COVID-19 vaccine demonstrated 100% efficacy and robust antibody responses in people between the ages of 12 and 15, according...

Pfizer starts evaluation of SARS-CoV-2 oral antiviral
Pfizer is advancing its clinical research of PF-07321332, a new investigational oral antiviral therapy against SARS-CoV-2, to evaluate the safety and...

Pyxis licenses 2 oncology ADC programs from Pfizer
Pyxis Oncology has entered into a worldwide license agreement with Pfizer for the development and commercialization of two antibody-drug conjugate (ADC)...

Can a single dose of a vaccine designed as 2 doses be effective?
Researchers suggested that two doses of a COVID-19 vaccine are more protective than a single dose, even if the interdose period is longer than recommended....